ReviewGastroenterology clinics of North America2012
Pancreatic cancer screening.
Review in Gastroenterology clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer.Metabolomics : Official journal of the Metabolomic Society · 2018Pooled it
- Bavachin inhibits cell viability and migration in human pancreatic cancer cells.microPublication biology · 2026Article
- Deep learning CT model for stratified diagnosis of pancreatic cystic neoplasms: multicenter development, validation, and real-world clinical impact.NPJ digital medicine · 2025Article
- Multiplexed Quantitation of Plasma Proteins by Targeted Mass Spectrometry for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2025Article
- Review
- The lncRNAIranian journal of public health · 2024Article
- Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening.Current oncology (Toronto, Ont.) · 2022Review
- Designing optimal allocations for cancer screening using queuing network models.PLoS computational biology · 2022Article
- Multidisciplinary management for Peutz-Jeghers syndrome and prevention of vertical transmission to offspring using preimplantation genetic testing.Orphanet journal of rare diseases · 2022Article
- Risk Factors for Pancreatic Cancer: Emerging Role of Viral Hepatitis.Journal of personalized medicine · 2022Review
- Current status of non-surgical treatment of locally advanced pancreatic cancer.World journal of gastrointestinal oncology · 2021Review
- Comparison of perioperative outcomes in pancreatic head cancer patients following either a laparoscopic or open pancreaticoduodenectomy with a superior mesenteric artery first approach.Annals of hepato-biliary-pancreatic surgery · 2021Article
- Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management.World journal of gastroenterology · 2021Review
- PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer.Translational cancer research · 2021Article
- Early Diagnosis of Pancreatic Cancer: The Key for Survival.Diagnostics (Basel, Switzerland) · 2020Review
- Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.Molecular biology reports · 2020Review
- Radiomics in stratification of pancreatic cystic lesions: Machine learning in action.Cancer letters · 2020Review
- Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.Familial cancer · 2019Article
- Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.Clinical epigenetics · 2019Article
- Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.World journal of oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Accumulating data indicate that clinically available abdominal imaging tests such as EUS and MRI/MRCP can detect asymptomatic precursor benign (IPMN, PanIN) and invasive malignant pancreatic neoplasms, such as ductal adenocarcinoma, in individuals with an inherited predisposition. These asymptomatic FPCs detected have been more likely to be resectable, compared to symptomatic tumors. The most challenging part of screening high-risk individuals is the selection of individuals with high-grade precursor neoplasms for preventive treatment (ie, surgical resection before development of invasive cancer). Ongoing and future research should focus on formulating and validating a model for FPC risk and neoplastic progression using patient characteristics, imaging, and biomarkers. The comparative cost and effectiveness of various approaches for screening and surveillance of high-risk individuals also deserves study. For now, screening is best performed in high-risk individuals within the research protocols in academic centers with multidisciplinary teams with expertise in genetics, gastroenterology, radiology, surgery, and pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.